Department of Preventive Medicine, Medical College of Yangzhou University, Yangzhou, China.
Department of Neurosurgery, Clinical Medical College of Yangzhou University, Yangzhou, China.
World Neurosurg. 2020 Jan;133:e135-e148. doi: 10.1016/j.wneu.2019.08.184. Epub 2019 Sep 3.
Decompressive hemicraniectomy (DHC) is widely applied for patients with traumatic brain injury (TBI). Although previous studies have indicated that DHC can lead to similar or worse outcomes compared with medical treatment (MT) in patients with TBI, recent trials have suggested the benefit of DHC for neurologic function recovery. Therefore, we performed this meta-analysis to assess the efficacy and functional outcomes of DHC in patients with TBI.
In accordance with PRISMA guidelines, we searched English and Chinese databases to identify relevant randomized controlled trials (RCTs) reporting DHC for TBI. The outcomes measures included mortality, favorable outcome, unfavorable outcome, postoperative intracranial pressure (ICP), adverse events with hematoma, and hospital stay.
Seven RCTs with a total of 779 patients with TBI were included in this meta-analysis. Compared with the MT group, the DHC group demonstrated significantly lower rates of mortality (P < 0.00001), postoperative ICP (P < 0.00001), and postoperative hematoma (P = 0.01), and significantly shorter hospital length of stay (P = 0.02). However, the rate of unfavorable outcomes was higher in the DHC group compared with the MT group (P = 0.0001).
Our results indicate that DHC could be effective in reducing the mortality rate, incidence of ICP, and hospital length of stay in patients with TBI. However, the proportion of patients surviving with unfavorable outcomes was significantly higher in the DHC group compared with the MT group. Despite the limitations of the meta-analysis, our findings target extremely important topic and provide important evidence to facilitate clinical decision making.
去骨瓣减压术(DHC)广泛应用于创伤性脑损伤(TBI)患者。尽管先前的研究表明,DHC 可能导致 TBI 患者的结局与药物治疗(MT)相似或更差,但最近的试验表明 DHC 有利于神经功能恢复。因此,我们进行了这项荟萃分析,以评估 DHC 在 TBI 患者中的疗效和功能结局。
根据 PRISMA 指南,我们检索了英文和中文数据库,以确定报告 DHC 治疗 TBI 的相关随机对照试验(RCT)。结局指标包括死亡率、良好结局、不良结局、术后颅内压(ICP)、血肿相关不良事件和住院时间。
本荟萃分析纳入了 7 项 RCT,共 779 例 TBI 患者。与 MT 组相比,DHC 组的死亡率(P<0.00001)、术后 ICP(P<0.00001)和术后血肿(P=0.01)发生率较低,住院时间较短(P=0.02)。然而,DHC 组的不良结局发生率高于 MT 组(P=0.0001)。
我们的结果表明,DHC 可有效降低 TBI 患者的死亡率、ICP 发生率和住院时间。然而,与 MT 组相比,DHC 组存活患者不良结局的比例显著更高。尽管荟萃分析存在局限性,但我们的研究结果针对一个极其重要的课题,为临床决策提供了重要依据。